Monitor next quarter for thyroid revenue growth sustainability and whether the company can maintain profitability without the one-time tax benefit. The pro forma comparison suggests underlying business improvement.
Price Chart
Executive Summary
Interpace Biosciences reported full-year 2025 revenue of $38.7 million and income from continuing operations of $25.0 million, driven by a 21% year-over-year increase in thyroid revenue and a one-time $21.2 million tax benefit from the release of a deferred tax valuation allowance. The company completed its transition to a thyroid-only diagnostics model after discontinuing PancraGEN.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $38.7 million, down 18% from $46.9 million in 2024
- Income from continuing operations was $25.0 million, including a one-time $21.2 million tax benefit
- Thyroid revenue grew 21% year-over-year in 2025
- Company transitioned to thyroid-only diagnostics after discontinuing PancraGEN in May 2025
- Pro forma 2024 revenue (thyroid-only) was $33.2 million, making 2025 revenue a 17% increase
Financial Impact
Revenue decreased 18% YoY but increased 17% on a pro forma thyroid-only basis; $21.2 million one-time tax benefit inflated earnings
Risk Factors
- Heavy reliance on one-time tax benefit inflates profitability
- Revenue decline on reported YoY basis despite pro forma improvement
- Transition risk from discontinuing PancraGEN product line
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014654 |
| Document: form8-k.htm | 0001493152-26-014654 |
| Document: 0001493152-26-014654-index-headers.html | 0001493152-26-014654 |
| Document: 0001493152-26-014654-index.html | 0001493152-26-014654 |
| Document: 0001493152-26-014654.txt | 0001493152-26-014654 |
| 8-K Data (Synthetic) | 0001493152-26-014654 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $5.27 $5.40 | ▲ +2.47% | ▲ +3.48% | $5.50 (+4.36%) |
Sep 30, 2026 26d ago | S-1/A | $6.39 $6.00 | ▼ −6.10% | ▼ −7.40% | $5.50 (−13.93%) |
Apr 1, 2026 29w ago | 8-K | $1.96 $2.30 | ▲ +17.47% | ▲ +13.85% | $5.50 (+180.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers